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Abstract	  	  
Introduction:	  There	  is	  a	  need	  to	  discover	  new	  methods	  of	  cost-­‐effective	  care	  as	  the	  healthcare	  system	  transitions	  to	  a	  model	  emphasizing	  quality	  outcomes.	  Medication	  prices	  continue	  to	  rise	  and	  must	  be	  considered	  when	  evaluating	  the	  cost	  of	  new	  approaches	  to	  treatment.	  Increased	  utilization	  of	  advanced	  practice	  pharmacists	  represents	  one	  solution	  to	  appropriate	  medication	  use	  in	  chronic	  disease	  state	  management.	  However,	  the	  effect	  on	  the	  cost	  of	  prescribed	  pharmacotherapy	  is	  unknown.	  	  
Objective:	  To	  determine	  the	  cost	  of	  medications	  prescribed	  to	  patients	  receiving	  care	  from	  both	  Clinical	  Pharmacist	  Practitioners	  (CPPs)	  and	  Primary	  Care	  Providers	  (PCP:	  physician,	  family	  nurse	  practitioner,	  and	  physician	  assistant)	  compared	  to	  those	  just	  receiving	  care	  from	  PCPs.	  
	  
Methods:	  This	  was	  a	  retrospective	  matched	  cohort	  analysis.	  Each	  cohort	  was	  matched	  by	  gender,	  age,	  and	  disease	  states	  of	  interest.	  There	  were	  130	  patients	  total,	  65	  in	  each	  cohort,	  seen	  at	  the	  University	  of	  North	  Carolina	  outpatient	  clinics	  between	  November	  2008	  and	  November	  2011.	  The	  primary	  endpoint	  was	  average	  medication	  cost	  per	  day	  per	  patient	  determined	  by	  the	  average	  wholesale	  price	  (AWP)	  of	  prescribed	  medications.	  The	  secondary	  endpoint	  was	  average	  number	  of	  therapy	  changes	  per	  year	  per	  patient.	  	  
	  
Results:	  There	  was	  no	  statistical	  difference	  in	  the	  average	  medication	  cost	  per	  day	  per	  patient	  in	  the	  CPP	  cohort	  versus	  PCP	  cohort	  ($38.52	  vs.	  $38.23,	  respectively;	  p	  =	  0.97).	  Patients	  managed	  by	  CPPs	  experienced	  a	  higher	  average	  number	  of	  therapy	  changes	  per	  year	  compared	  to	  patients	  only	  managed	  by	  PCPs	  	  (21.1	  vs.	  15.5,	  respectively;	  p	  =	  0.032).	  	  
	  
Conclusions:	  CPPs	  utilized	  within	  the	  healthcare	  team	  did	  not	  result	  in	  an	  increased	  medication	  cost	  despite	  being	  correlated	  with	  more	  therapy	  changes.	  
	  
Introduction	  
	   	  The	  introduction	  of	  the	  Affordable	  Care	  Act	  (ACA)	  in	  2010	  catalyzed	  a	  reform	  within	  healthcare.	  Once	  founded	  on	  fee	  for	  service,	  healthcare	  is	  progressing	  to	  a	  model	  that	  incentivizes	  efficient	  and	  high-­‐quality	  care.	  Hospitals	  not	  meeting	  performance	  standards,	  such	  as	  target	  readmission	  rates,	  will	  be	  subject	  to	  financial	  penalties	  with	  respect	  to	  Medicare	  reimbursements.1	  Similarly,	  incentives	  were	  created	  to	  reduce	  hospital-­‐acquired	  conditions	  and	  those	  within	  the	  lowest	  quartile	  can	  also	  lose	  1%	  of	  Medicare	  reimbursements.1	  Changes	  to	  the	  medical	  landscape,	  such	  as	  Accountable	  Care	  Organizations	  (ACO),	  bundled	  payments	  for	  care	  improvement,	  and	  the	  patient	  centered	  medical	  home	  are	  a	  few	  strategies	  already	  utilized	  to	  increase	  coordination	  of	  care,	  achieve	  these	  standards,	  and	  reduce	  spending.1,2	  	  Despite	  these	  efforts,	  total	  spending	  on	  healthcare	  continues	  to	  rise.	  In	  2013,	  healthcare	  costs	  were	  $2.9	  trillion	  with	  retail	  prescription	  drugs	  contributing	  $271.1	  billion	  nationally.3	  Medication	  spending	  increased	  by	  12.6%	  in	  2014,	  and	  the	  Centers	  for	  Medicare	  and	  Medicaid	  Services	  (CMS)	  expect	  a	  growth	  of	  6.3%	  annually	  from	  2015-­‐2024	  partly	  due	  to	  the	  increase	  in	  newly	  insured	  patients	  under	  the	  ACA.3,4	  Pharmacists	  are	  medication	  experts	  and	  expanding	  their	  clinical	  services	  can	  reduce	  overall	  healthcare	  spending.	  The	  Asheville	  Project	  found	  consultations	  with	  community-­‐based	  pharmacists	  reduced	  the	  average	  amount	  paid	  per	  patient	  year	  from	  the	  insurer’s	  perspective	  for	  both	  cardiovascular	  and	  diabetes	  related	  medical	  costs.	  5,6	  However,	  medication	  expenditures	  increased	  in	  both	  studies	  by	  as	  much	  as	  290%.	  	  Collaborative	  drug	  therapy	  management	  (CDTM),	  defined	  as	  a	  collaborative	  practice	  agreement	  between	  a	  physician	  and	  pharmacist	  that	  allows	  pharmacists	  to	  initiate,	  monitor,	  and	  adjust	  drug	  regimens,	  is	  permitted	  to	  varying	  degrees	  in	  48	  states.7	  However,	  four	  states,	  which	  include	  California,	  Montana,	  New	  Mexico,	  and	  North	  Carolina,	  enable	  expanded	  scopes	  of	  practice	  and	  prescribing	  authority.8,9	  North	  Carolina	  passed	  the	  Clinical	  Pharmacist	  Practitioner	  Act	  on	  July	  1,	  2000	  enabling	  pharmacists	  meeting	  specific	  post-­‐graduate	  training	  to	  provide	  drug	  therapy	  management	  under	  a	  protocol	  of	  a	  supervising	  physician.10,11	  Drug	  therapy	  management	  includes	  initiating	  or	  modifying	  drug	  therapies,	  which	  may	  include	  controlled	  substances,	  and	  ordering	  lab	  tests.	  There	  is	  a	  lack	  of	  literature	  examining	  the	  effects	  advanced	  practice	  pharmacists,	  such	  as	  CPPs,	  have	  on	  patient	  outcomes	  and	  cost	  of	  care.	  The	  medication	  arm	  of	  the	  APPLE-­‐NC	  study	  aims	  to	  explore	  the	  effect	  of	  CPPs	  on	  medication	  costs	  for	  Medicare	  beneficiaries.	  	  
Methods	  	  
Design	  and	  participants	  This	  was	  a	  36-­‐month	  retrospective	  matched	  cohort	  study.	  The	  study	  population	  consisted	  of	  every	  Medicare	  beneficiary	  seen	  by	  a	  PCP	  or	  CPP	  at	  the	  University	  of	  North	  Carolina	  at	  Chapel	  Hill	  Healthcare	  System	  (UNC)	  for	  chronic	  disease	  management.	  The	  outpatient	  clinics	  included:	  Internal	  Medicine,	  Endocrine,	  Family	  Medicine,	  Outpatient	  Oncology,	  Solid	  Organ	  Transplant,	  Geriatrics,	  and	  Anesthesia	  Spine	  Center.	  The	  North	  Carolina	  Translational	  and	  Clinical	  Sciences	  Institute	  collected	  claims	  data	  on	  every	  patient	  seen	  by	  either	  a	  CPP	  as	  a	  referral	  from	  the	  patient’s	  PCP	  or	  managed	  by	  a	  PCP	  alone	  at	  the	  clinics.	  All	  eligible	  patients	  were	  separated	  into	  either	  a	  CPP	  or	  PCP	  cohort	  and	  matched	  by	  age,	  gender,	  and	  ICD-­‐9	  codes	  for	  chronic	  disease	  states	  of	  interest	  using	  SAS	  software,	  version	  9.2	  (SAS	  Institute,	  Inc.,	  Cary,	  NC	  (2008))	  and	  randomly	  selected	  for	  inclusion	  using	  Microsoft	  Excel®.	  	  	  
Inclusion	  and	  Exclusion	  Criteria	  Medicare	  patients	  were	  included	  if	  they	  were	  seen	  between	  11/01/08	  through	  11/01/11.	  All	  patients	  required	  an	  ICD-­‐9	  code	  for	  one	  of	  the	  following	  chronic	  disease	  states	  of	  interest:	  hypertension,	  type	  2	  diabetes	  mellitus,	  or	  peripheral	  neuropathy.	  These	  disease	  states	  were	  selected	  because	  of	  their	  prevalence	  and	  associated	  complexity	  of	  pharmacotherapy	  management.	  Patients	  in	  the	  CPP	  cohort	  were	  included	  in	  the	  analysis	  if	  they	  had	  at	  least	  two	  CPP	  visits	  in	  addition	  to	  two	  PCP	  visits	  during	  the	  study	  period.	  This	  requirement	  was	  to	  demonstrate	  continuity	  of	  care	  between	  the	  CPP	  and	  PCP.	  Patients	  in	  the	  PCP	  cohort	  were	  included	  if	  they	  were	  seen	  at	  least	  twice	  by	  a	  PCP	  during	  the	  study	  period	  and	  were	  not	  managed	  by	  a	  CPP.	  Dual	  eligible	  Medicare	  and	  Medicaid	  patients	  were	  excluded.	  	  
	  
Outcomes	  The	  primary	  endpoint	  was	  the	  difference	  in	  average	  medication	  cost	  per	  day	  per	  patient.	  The	  secondary	  endpoint	  was	  average	  number	  of	  therapy	  changes	  per	  year	  per	  patient	  defined	  as	  a	  dose	  increase	  or	  decrease,	  or	  drug	  initiation	  or	  discontinuation.	  	  	  
Medication	  History	  	  Medications	  were	  tracked	  using	  WebCIS,	  an	  electronic	  medical	  record	  (EMR)	  utilized	  by	  UNC	  during	  the	  study	  period.	  Only	  prescription	  medications	  were	  included	  in	  the	  cost	  analysis.	  Herbal	  supplements,	  vitamins,	  minerals,	  and	  medications	  only	  available	  over-­‐the-­‐counter	  were	  excluded.	  These	  products	  were	  not	  always	  initiated	  by	  the	  practitioner	  and	  therefore	  were	  not	  accurately	  recorded	  in	  the	  EMR.	  	  	  




Statistical	  analysis	  Assuming	  a	  medium	  Cohen’s	  effect	  size	  of	  0.5	  standard	  deviations,	  a	  sample	  size	  of	  130	  subjects	  was	  needed	  to	  achieve	  an	  80%	  power	  using	  a	  two-­‐tailed	  t-­‐test	  and	  alpha	  of	  0.05.	  Total	  cost	  and	  therapy	  changes	  were	  analyzed	  using	  two-­‐tailed	  matched	  pairs	  t-­‐tests.	  	  
Results	  
	  Baseline	  demographics	  are	  listed	  in	  Table	  1.	  The	  average	  age	  was	  64	  years	  and	  61.5%	  of	  all	  patients	  were	  female.	  Baseline	  clinical	  variables	  are	  shown	  in	  Table	  2.	  Mean	  HbA1c	  was	  significantly	  higher	  in	  the	  CPP	  cohort	  compared	  to	  the	  PCP	  cohort	  (7.5	  vs.	  6.8,	  respectively;	  p	  =	  0.023).	  	  	  
Table	  1.	  Baseline	  demographics.	  
	  	   CPP	  (n=65)	   PCP	  (n=65)	  
Female	  –	  no.	  (%)	   40	  (61.5)	   40	  (61.5)	  
Male	  –	  no.	  (%)	   25	  (38.5)	   25	  (38.5)	  
Age,	  Average	  –	  year	   64	   64	  
Age	  <	  65	  years	  –	  no.	  (%)	   27	  (41.5)	   27	  (41.5)	  
Age	  ≥	  65	  years	  –	  no.	  (%)	   38	  (58.5)	   38	  (58.5)	  
Caucasian	  –	  no.	  (%)	   41	  (63.1)	   38	  (58.5)	  
African	  American	  –	  no.	  (%)	   22	  (33.8)	   26	  (40.0)	  
Hispanic	  –	  no.	  (%)	   1	  (1.5)	   1	  (1.5)	  
Asian	  –	  no.	  (%)	   1	  (1.5)	   0	  (0.0)	  	   	  	   	  	  
Hypertension	  –	  no.	  (%)	   63	  (96.9)	   63	  (96.9)	  
Diabetes,	  Type	  2	  –	  no.	  (%)	   28	  (43.1)	   36	  (55.4)	  
Peripheral	  Neuropathy	  –	  no.	  (%)	   34	  (52.3)	   31	  (47.7)	  
	  	   	  	   	  	  
Hypertension	  only	  –	  no.	  (%)	   16	  (24.6)	   14	  (21.5)	  
Diabetes	  only	  –	  no.	  (%)	   0	  (0.0)	   0	  (0.0)	  
Peripheral	  Neuropathy	  only	  –	  no.	  (%)	   2	  (3.1)	   2	  (3.1)	  
Hypertension	  and	  Diabetes	  –	  no.	  (%)	   15	  (23.1)	   20	  (30.8)	  
Hypertension	  and	  Peripheral	  Neuropathy	  –	  no.	  (%)	   19	  (29.2)	   13	  (20.0)	  
Diabetes	  and	  Peripheral	  Neuropathy	  –	  no.	  (%)	   0	  (0.0)	   0	  (0.0)	  
All	  Disease	  States	  of	  Interest	  –	  no.	  (%)	   13	  (20.0)	   16	  (24.6)	  	   	   	  
Smoker	  –	  no.	  (%)	   11	  (16.9)	   11	  (16.9)	  
Non-­‐smoker	  –	  no.	  (%)	   54	  (83.1)	   54	  (83.1)	  









Table	  2.	  Baseline	  clinical	  variables.	  	  
	   CPP	  (n=65)	   PCP	  (n=65)	   	  
Mean	   95%	  CI	   Mean	   95%	  CI	   p-­‐value	  
Body	  Mass	  Index	  –	  kg/m2	   31.2	   29.4	  -­‐	  33.0	   31.0	   29.3	  -­‐	  32.6	   0.4878	  
10	  year	  CVD	  risk	  –	  %	   23.3	   18.1	  -­‐	  28.5	   22.7	   17.8	  –	  27.7	   0.802	  
Systolic	  Blood	  Pressure	  –	  mmHg	   132.4	   127.3	  -­‐	  137.5	   136.6	   131.2	  -­‐	  142.0	   0.267	  
Total	  Cholesterol	  –	  mg/dL	   184.2	   169.4	  –	  199.0	   182.4	   168.0	  -­‐	  196.8	   0.859	  
High	  Density	  Lipoprotein	  –	  mg/dL	   51.2	   46.6	  –	  55.8	   53.3	   48.2	  -­‐	  58.3	   0.536	  
Hemoglobin	  A1c	  –	  %	  	   7.5	   6.8	  –	  8.2	   6.8	   6.2	  –	  7.3	   0.023	  
Brief	  Pain	  Score	   7.2	   6.2	  –	  8.2	   6.5	   8.0	  –	  5.0	   0.368	  
	  There	  was	  no	  statistical	  difference	  in	  the	  primary	  endpoint	  of	  average	  medication	  cost	  per	  day	  per	  patient.	  The	  medications	  prescribed	  to	  the	  CPP	  cohort	  cost	  on	  average	  $38.52	  per	  day	  per	  patient	  and	  $38.23	  per	  day	  per	  patient	  in	  the	  PCP	  cohort	  (mean	  difference	  $0.29;	  p	  =	  0.97)	  (Table	  3).	  Patients	  in	  the	  CPP	  cohort	  required	  more	  average	  therapy	  changes	  per	  year	  than	  patients	  in	  the	  PCP	  cohort	  (21.1	  vs.	  15.1,	  respectively;	  p=0.032).	  	  	  
Table	  3:	  	  Average	  difference	  in	  medication	  cost	  per	  day	  and	  therapy	  changes	  per	  year.	  
	   CPP	   PCP	   Mean	  Difference	   P-­‐Value	  
Medication	  Cost,	  Average	  –	  $/day	   $38.52	   $38.23	   $0.29	   0.97	  
Therapy	  Changes,	  Average	  –	  changes/year	   21.1	   15.5	   5.6	   0.032	  	  
Discussion	  	  Medication	  cost	  is	  an	  important	  factor	  when	  assessing	  overall	  healthcare	  efficiency.	  The	  medication	  arm	  of	  the	  APPLE-­‐NC	  study	  provided	  an	  estimate	  of	  the	  total	  cost	  of	  medications	  prescribed	  to	  Medicare	  patients	  managed	  only	  by	  PCPs	  compared	  to	  those	  also	  managed	  by	  CPPs.	  A	  matched	  cohort	  design	  was	  utilized	  to	  reduce	  variability	  in	  disease	  state	  complexity	  while	  still	  enabling	  enough	  eligible	  patients	  for	  inclusion	  in	  the	  analysis.	  Age,	  gender,	  and	  three	  disease	  states	  of	  interest	  were	  identified	  for	  this	  purpose.	  Hypertension	  and	  type	  2	  diabetes	  mellitus	  were	  selected	  because	  of	  their	  known	  prevalence	  within	  the	  UNC	  outpatient	  clinics	  and	  ease	  of	  monitoring	  disease	  state	  management.	  In	  addition	  to	  total	  cost	  of	  care,	  the	  overall	  APPLE-­‐NC	  study	  analyzed	  efficacy	  of	  treatment.	  Hypertension	  and	  diabetes	  mellitus	  have	  target	  clinical	  biomarkers	  (blood	  pressure	  and	  glycosylated	  hemoglobin,	  respectively)	  recommended	  by	  national	  guidelines	  that	  allowed	  for	  objective	  comparison	  between	  cohorts.	  Peripheral	  neuropathy	  is	  a	  subjective	  measure	  and	  therefor	  not	  as	  easily	  comparable,	  however,	  it	  was	  selected	  because	  of	  its	  complexity	  in	  pharmacotherapy	  management	  and	  presumed	  interrelatedness	  with	  diabetes	  mellitus	  at	  UNC	  clinics.	  After	  randomization,	  it	  was	  discovered	  that	  some	  patients	  had	  disease	  states	  of	  interest	  that	  were	  not	  linked	  with	  the	  appropriate	  ICD-­‐9	  codes.	  For	  example,	  some	  patients	  carrying	  only	  the	  ICD-­‐9	  code	  for	  hypertension	  also	  had	  diabetes.	  Therefore,	  cohorts	  were	  accurately	  matched	  on	  gender	  and	  age	  only.	  The	  accurate	  diagnoses	  per	  the	  EMR	  are	  reflected	  in	  table	  2.	  	  	  Baseline	  characteristics	  were	  similar	  between	  both	  cohorts	  except	  for	  mean	  Hemoglobin	  A1c,	  which	  was	  significantly	  higher	  in	  the	  CPP	  cohort.	  It	  was	  hypothesized	  that	  that	  the	  utilization	  of	  advanced	  practice	  pharmacists	  would	  be	  associated	  with	  a	  higher	  cost	  of	  medications	  because	  patients	  managed	  by	  pharmacists	  generally	  have	  multiple	  comorbidities,	  complex	  drug	  regimens,	  or	  are	  refractory	  to	  standard	  therapies.13,14	  However,	  there	  was	  no	  significant	  difference	  in	  medication	  costs	  despite	  more	  therapy	  changes	  in	  the	  CPP	  cohort.	  This	  may	  be	  caused	  by	  a	  few	  reasons	  that	  were	  not	  directly	  measured	  within	  this	  study:	  1)	  CPPs	  utilize	  more,	  low	  cost	  medications	  to	  optimize	  therapy	  2)	  The	  adjustments	  made	  by	  CPPs	  were	  primarily	  for	  dose	  optimization,	  not	  addition	  of	  new	  therapies	  3)	  Number	  of	  therapy	  changes	  does	  not	  drive	  overall	  cost	  of	  medications.	  Additionally,	  a	  confounding	  variable	  is	  that	  CPPs	  participated	  in	  an	  anticoagulation	  clinic	  included	  in	  the	  study.	  This	  clinic	  may	  have	  contributed	  to	  the	  large	  number	  of	  therapy	  changes	  per	  year,	  as	  CPPs	  were	  influential	  in	  adjusting	  warfarin	  doses.	  	  
Data	  collected	  in	  this	  study	  were	  included	  in	  the	  overall	  APPLE-­‐NC	  study,	  which	  found	  patients	  managed	  by	  PCPs	  in	  conjunction	  with	  CPPs	  were	  as	  likely	  to	  reach	  their	  disease	  state	  goals	  as	  patients	  only	  managed	  by	  PCPs.	  Additionally,	  there	  was	  no	  difference	  in	  medical	  charges,	  defined	  as	  the	  cost	  of	  inpatient	  admissions,	  emergency	  department	  visits,	  and	  outpatient	  visits	  identified	  using	  Medicare	  claims	  data.15	  	  
Limitations	  There	  are	  limitations	  that	  should	  be	  considered	  when	  assessing	  the	  impact	  of	  the	  medication	  arm	  of	  the	  APPLE-­‐NC	  study.	  It	  has	  a	  very	  small	  sample	  size	  of	  130	  patients.	  However,	  many	  more	  patients	  qualified	  for	  inclusion	  and	  could	  be	  utilized	  for	  subsequent	  research.	  Although	  the	  cohorts	  were	  correctly	  matched	  by	  age	  and	  gender,	  there	  were	  inconsistencies	  with	  the	  claims	  data	  and	  diagnoses	  recorded	  in	  the	  EMR.	  This	  may	  partially	  be	  due	  to	  a	  limited	  search	  method	  for	  disease	  states.	  Another	  limitation	  is	  the	  use	  of	  AWP	  for	  medication	  prices.	  Pharmacies	  and	  healthcare	  systems	  may	  obtain	  medications	  at	  prices	  lower	  than	  AWP,	  depending	  on	  contractual	  agreements,	  and	  the	  true	  cost	  would	  be	  more	  accurately	  reflected	  in	  Medicare	  claims	  data.	  AWP	  was	  also	  limited	  to	  one	  year.	  However,	  this	  was	  done	  to	  reduce	  the	  effect	  of	  AWP	  variability	  that	  may	  not	  accurately	  correlate	  with	  medication	  price	  fluctuations.	  Additionally,	  the	  data	  set	  only	  captured	  medical	  visits	  within	  the	  UNC	  Healthcare	  system.	  Medications	  prescribed	  at	  visits	  to	  outside	  hospitals,	  such	  as	  an	  urgent	  care	  facility,	  would	  not	  be	  included	  in	  the	  total	  costs.	  As	  previously	  stated,	  there	  is	  an	  outpatient	  anticoagulation	  clinic	  that	  CPPs	  participate	  in,	  which	  could	  confound	  the	  results	  of	  total	  therapy	  changes.	  As	  a	  retrospective	  study,	  there	  are	  limitations	  to	  extracting	  information	  from	  the	  EMR.	  There	  may	  be	  differences	  in	  documentation	  styles	  between	  CPPs	  and	  PCPs	  affecting	  the	  quality	  of	  data	  utilized	  to	  generate	  medication	  histories.	  	  	  
Implications	  Although	  CPPs	  appear	  to	  contribute	  expertise	  without	  increasing	  overall	  medication	  spending,	  there	  are	  barriers	  to	  implementing	  similar	  models	  ubiquitously.	  	  Pharmacists	  working	  collaboratively	  with	  physicians	  are	  not	  reimbursed	  directly	  for	  their	  services,	  and	  must	  use	  an	  “incident	  to”	  billing	  method.16	  CPT	  codes	  range	  from	  99211	  to	  99215,	  often	  referred	  to	  as	  levels	  1-­‐5,	  with	  increasing	  complexity	  and	  fees	  respectively.	  Many	  CPPs	  are	  required	  to	  bill	  as	  a	  Level	  1	  visit,	  which	  is	  described	  as	  requiring	  five	  minutes	  typically	  to	  manage	  minimal	  problems	  without	  the	  need	  of	  a	  physician	  (Table	  4).17	  Scott	  et	  al.	  found	  CPPs	  billed	  on	  average	  $51,322	  during	  1,658	  patient	  encounters	  per	  year	  from	  2007-­‐2011	  in	  anticoagulation	  and	  pharmacotherapy	  clinics	  at	  the	  Mountain	  Area	  Health	  Education	  Center	  Family	  Health	  Center.	  16	  They	  estimated	  these	  charges	  would	  increase	  to	  an	  average	  of	  $110,854	  per	  year	  and	  $164,565	  per	  year	  if	  CPPs	  could	  bill	  at	  levels	  3	  and	  4,	  respectively.	  Lack	  of	  provider	  status	  and	  ability	  to	  bill	  for	  services	  align	  with	  the	  perceived	  barriers	  of	  CPPs.	  It	  was	  the	  most	  common	  challenge	  to	  clinical	  practice	  noted	  by	  55.2%	  of	  active	  and	  inactive	  CPPs	  responding	  to	  a	  survey	  conducted	  in	  2011.18	  Currently,	  there	  is	  legislation	  within	  congress,	  H.R.	  592	  and	  S.	  314,	  that	  amends	  title	  XVIII	  of	  the	  Social	  Security	  Act.	  If	  passed,	  pharmacists	  will	  receive	  “80	  percent	  of	  the	  lesser	  of	  the	  actual	  charge	  or	  85	  percent	  of	  the	  fee	  schedule	  amount	  provided	  under	  section	  1848	  if	  such	  services	  had	  been	  furnished	  by	  a	  physician.”19	  Increasing	  the	  compensation	  to	  match	  the	  services	  pharmacists	  are	  already	  providing	  will	  magnify	  their	  ability	  to	  deliver	  cost-­‐efficient	  healthcare.	  	  	  
Conclusion	  	  This	  study	  demonstrated	  that	  the	  involvement	  of	  advanced	  practice	  pharmacists	  in	  chronic	  disease	  state	  management	  did	  not	  result	  in	  a	  difference	  in	  total	  medication	  costs	  despite	  an	  increased	  number	  of	  therapy	  changes.	  The	  overall	  APPLE-­‐NC	  trial	  can	  serve	  as	  the	  foundation	  for	  other	  health	  systems	  to	  evaluate	  the	  care	  delivered	  by	  pharmacists	  on	  a	  larger	  scale	  and	  advocate	  for	  their	  recognition	  as	  providers.	  	  	  	  	  	  	  	  	  	  
Table	  4:	  CPT/HCPCS	  code	  descriptions.*	  
Code	   Code	  Description	   Problems	   Time	  Involved	  
(minutes)	  
Comments	  
99211	   No	  documentation	  requirements;	  may	  not	  require	  the	  presence	  of	  a	  physician	   Minimal	   5	   “Level	  1”	  visit	  
99212	   At	  least	  two	  of	  the	  following:	  problem-­‐focused	  history,	  problem-­‐focused	  examination,	  straightforward	  decision	  making	   Self-­‐limited	  or	  minor	   10	   “Level	  2”	  visit	  
99213	   At	  least	  two	  of	  the	  following:	  expanded	  problem-­‐focused	  history,	  expanded	  problem-­‐focused	  examination,	  medical	  decision	  making	  of	  low	  complexity	  
Low	  to	  moderate	  severity	   15	   “Level	  3”	  visit	  
99214	   At	  least	  two	  of	  the	  following:	  detailed	  history,	  detailed	  examination,	  medical	  decision	  making	  of	  moderate	  complexity	   Moderate	  to	  high	  severity	   25	   “Level	  4”	  visit	  
99215	   At	  least	  two	  of	  the	  following:	  comprehensive	  history,	  comprehensive	  examination,	  medical	  decision	  making	  of	  high	  complexity	   Moderate	  to	  high	  severity	   40	  
“Level	  5”	  visit,	  typically	  involves	  a	  complete	  physical	  examination	  *Adapted	  from	  references	  16	  and	  17.	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